Introduction
The history of South Korean bioindustry shows the existence of three stages: 
Research Portfolio
In areas such as fermentation technology, South Korea has reached the technological level of industrialized countries. However, a report by the KRIBB suggested that other areas of technology, such as separation technology and biomaterials, are still at an early stage of development. c) Strengthening and promoting bioclusters. This will be achieved through the construction of Korea Biohub, strengthening of existing bioclusters, promotion of the use of micro-biochip production platforms and establishment of platforms supporting industrialization of BIT technology. The construction of advanced biopharmaceutical production complexes and bulk vaccine production complexes will also be undertaken.
d) Promoting global networks. The establishment of investment/consultant companies with participation from the public sector and private and foreign companies is hoped to support long-term investment of biotechnology in South Korea. Additional benefits are perceived through R&D collaboration with foreign countries, training international standard specialists and networking among domestic and foreign association, companies and governments. Table 1 shows the diversity of South Korean bioindustry. South Korean bioindustry's mid-term and next generation projects target the development of therapeutic protein by animal cell culture, development of biomaterials by intelligence-type bioinformatics, development of gene therapy for currently incurable diseases, mass production of protein-DNA chip systems and development of high value-added protein. Longer term goals include immunomodulator, drug delivery systems, gene therapy, cell therapy and cGMP technology.
Core Competencies and Capabilities
There were 605 bioindustry companies in 2003 of which 173 were in R&D and 432 in sales. A breakdown of companies by size reveals approximately 30 large size (operating fully integrated R&D, production and marketing divisions), 70 medium size (focused on the competitive core products) and more than 500 small size and/or venture groups (individually concentrated on the Niche Fields of R&D, production or marketing). The bioindustry workforce was 11,013 in 2003 with 5808 (53%) in R&D and 5205 (47%) in manufacturing. Market size in 2003 was US$1332 million, which included 61% biopharmaceuticals and 39% non-pharmaceuticals (Table 2) . Product distribution was 68% and 32% for domestic and export products, respectively. The market was valued at around US$1598 million in 2004. 
Conclusion (SWOT)
a
Areas

Contents
Biochemicals
Biopolymer, industrial enzymes, organic acids, amino acids, reagents and kits, bioagrochemicals, etc. 
